CANbridge Receives Hong Kong Department of Health Market Approval for Nerlynx®

Nov 05, 2019

CANbridge Pharmaceuticals’ Hunterase® Granted Priority Review by the Chinese National Medical Products Administration

Sep 09, 2019

CANbridge Pharmaceuticals Appoints Senior Vice President, Rare Disease Commercial Operations

Jul 30, 2019

CANbridge Pharmaceuticals Submits New Drug Application for Hunterase® for the Treatment of Hunter Syndrome in China

Jul 29, 2019

CANbridge Pharmaceuticals Appoints Chief Financial Officer and Interim Chief Medical Officer

Apr 25, 2019

CANbridge Pharmaceuticals and WuXi Biologics Expand Rare Disease Therapeutics Partnership

Jan 08, 2019

CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome

Jan 07, 2019